Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (RNN)

RNN RSS Feed
Add RNN Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 12/10/2014 10:23:07 AM - Followers: 194 - Board type: Free - Posts Today: 0



   
 



http://www.rexahn.com/cms/     

http://finance.yahoo.com/q/ks?s=RNN

About

Rexahn’s goal is to be a world leader in the discovery and development of new drugs to treat cancer. By developing compounds which specifically target cancer cells, excluding healthy tissue, Rexahn’s drug candidates may demonstrate increased efficacy and reduced toxicity- efficacy against multiple drug resistant cancer cells and synergism with existing cytotoxic compounds. Utilizing a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling, nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.

Rexahn’s core scientific expertise in the understanding of signal transduction processes involved in cancer cell growth is producing a drug portfolio with significant potential clinical value.
 

Today, our clinical development pipeline consists of three novel compounds:

Archexin® (Phase IIa) a best-in-class compound that blocks both the activated and native forms of Akt1 and has FDA orphan drug designation for the treatment of pancreatic cancer, ovarian cancer, stomach cancer, RCC, and glioblastoma.

RX-3117 (Phase I) a best-in-class compound that inhibits DNA and RNA synthesis, and exhibits high oral bioavailability. In comparison, RX-3117 may have a better safety profile than gemcitabine, the current first-line therapy for pancreatic and other cancers.

SupinoxinTM (RX-5902) (Phase I) a first-in-class small molecule that inhibits the phosphorylated p68 RNA helicase, a protein that plays a key role in cancer growth, progression and metastasis.

These lead clinical drugs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant product pipeline of innovative medicines that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company- one with the expertise to develop cures for significant diseases of our time.
 

Rexahn Pipeline


 

Management Team



Peter Suzdak, Ph.D.
Chief Executive Officer

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University




ANALYST COVERAGE
 
Roth Capital Partners, LLC
   Joseph Pantginis, Ph.D.
646-358-1907

jpantginis@roth.com

Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718

ehe@maximgrp.com

H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546

afein@hcwco.com


INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RNN
Current Price
Volume:
Bid Ask Day's Range
Wiki
RNN News: Statement of Changes in Beneficial Ownership (4) 12/03/2014 04:38:05 PM
RNN News: Initial Statement of Beneficial Ownership (3) 12/03/2014 04:29:29 PM
RNN News: Current Report Filing (8-k) 12/03/2014 04:19:34 PM
RNN News: Current Report Filing (8-k) 10/03/2014 04:24:48 PM
RNN News: Rexahn Pharmaceuticals to Present at the BioPharm America™ 2014 in Boston, Massachusetts, USA 09/16/2014 09:00:00 AM
PostSubject
#2800   RNN presentation today .. . jaytea 12/10/14 10:23:06 AM
#2799   PS: We have three near-term catalysts over the DorianGray 12/09/14 11:50:53 PM
#2798   Up? DorianGray 12/09/14 11:33:15 PM
#2797   That was very interesting info and sounds like ttubular 12/09/14 08:52:43 PM
#2796   Life Sciences interview with Rexahn CEO Peter Suzdak Biovestor79 12/09/14 08:02:53 PM
#2795   No follow through today unless there is a ttubular 12/09/14 02:00:01 PM
#2794   Nice move up maybe someone knows we r ttubular 12/09/14 08:32:33 AM
#2793   Wake me when we hit $10.....back to bed. DorianGray 12/09/14 12:20:46 AM
#2792   Nice day + 7% harmsen 12/08/14 01:43:16 PM
#2791   looks like it pops every jan 1st, than blulotus 12/05/14 04:03:27 PM
#2790   Just an SA article from yesterday: seekingalpha.com/article/2694025-update- Theo 11/20/14 09:10:38 AM
#2789   In my opinion, with their presentations at conferences Wardenclyffe 11/14/14 08:24:42 PM
#2788   Rexahn Pharmaceuticals Reports Third Quarter 2014 Financial Results GDCT CAPITAL 11/14/14 02:29:31 PM
#2787   I'm liking this 3 year 1 week chart GDCT CAPITAL 11/14/14 02:22:58 PM
#2786   LOL actually, it is indeed a coincidence. I Wardenclyffe 11/10/14 01:29:27 PM
#2785   Borrero and Wardenclyftee. I am holding quite a shanak10 11/08/14 08:22:32 PM
#2784   Borrero: I'm with you, and I agree. All Wardenclyffe 11/08/14 09:56:31 AM
#2783   Wardenclyffe : Another weeks goes by, and no Borrero 11/08/14 07:00:55 AM
#2782   Don't be surprised "if" we hear something out Wardenclyffe 11/04/14 02:27:39 PM
#2781   Wardenclyffe : I used to post like crazy, Borrero 11/04/14 11:08:16 AM
#2780   Thanks Borrero! Same to you, and thank you Wardenclyffe 11/04/14 01:10:52 AM
#2779   Wardenclyffe: It is impossible to post on the Borrero 11/03/14 10:46:25 PM
#2778   Agreed! Only reason we wouldn't is if they Biovestor79 11/02/14 08:00:56 PM
#2777   You are mistaken if you really think this. Wardenclyffe 10/28/14 10:45:33 PM
#2776   For the year? Rofl GDCT CAPITAL 10/28/14 08:08:59 PM
#2775   Incorrect, lots of news to come. Trail updates Biovestor79 10/28/14 07:58:00 PM
#2774   They already had their news for the year nutriman24 10/28/14 07:20:05 PM
#2773   POSSIBLE NEWS COMING ON THE 5th? "Rexahn Pharmaceuticals Wardenclyffe 10/28/14 02:25:42 PM
#2772   I wouldn't expect partnership news until the new Biovestor79 10/24/14 07:26:12 PM
#2771   No news for a while is that a jomama33 10/24/14 02:16:42 AM
#2770   Here comes the boom I hope... odoylemark 10/22/14 03:38:14 PM
#2769   http://seekingalpha.com/article/2545605-rexahns-new-nanotechnology-patent-create harmsen 10/07/14 12:04:17 PM
#2768   That sounds about right. I love their enthusiasm Heimie1 10/05/14 09:01:37 AM
#2767   They first started developing drugs for erectile dysfunction GDCT CAPITAL 10/04/14 08:56:25 PM
#2766   8K filed Friday: "Changes in Registrant’s Certifying Accountant." Theo 10/04/14 10:27:37 AM
#2765   Over 8 years in research and still no Heimie1 10/03/14 05:15:17 PM
#2764   My fingers are crossed here... I wouldnt put odoylemark 09/26/14 10:36:40 AM
#2763   http://seekingalpha.com/article/2521075-rexahn-update-a-partnership-is-all-the-m BONGWHOLE 09/25/14 02:11:05 PM
#2762   http://www.mideasttime.com/rexahn-pharmaceuticals-sees-significant-decline-in-sh BONGWHOLE 09/25/14 02:09:04 PM
#2761   $$ RNN $$--THIS WILL SURELY HIT $1+ BY BONGWHOLE 09/25/14 01:53:57 PM
#2760   Back in at .82....sold last time at $1.45....things tradinfool5 09/25/14 01:46:20 PM
#2759   We'll if that's his response when asked at JDV57 09/25/14 12:21:37 PM
#2758   And I am sure all the meetings about kpisme 09/25/14 10:07:27 AM
#2757   No reverse split till after Partnership per CEO JDV57 09/25/14 06:06:48 AM
#2756   Sounds like they are getting ready for that kpisme 09/24/14 10:37:16 PM
#2755   Roth Capital reiterates its Buy rating and $3 PepsiNBuds 09/24/14 08:26:07 PM
#2754   http://www.marketwatch.com/story/rexahn-receives-fda-orphan-drug-designation-for onthelak42 09/24/14 08:01:05 PM
#2753   AH volume is ridic! JDV57 09/24/14 06:29:13 PM
#2752   Related Quotes shanak10 09/24/14 04:51:58 PM
#2751   Havent paid much attention to RNN but i odoylemark 09/24/14 11:06:21 AM
PostSubject